| NVUS - Novus Therapeutics Inc (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Novus Therapeutics Inc is engaged in the biotechnology sector. As a pharmaceutical company, it is focused on the acquisition, development, and commercialization of ear, nose, and throat related products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |